| Title: |
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome |
| Authors: |
Huls, GerwinAff1, IDs0027702406033y_cor1; Chitu, Dana A.Aff2, Aff18; Tick, LidwineAff3; Boersma, RinskeAff4; Breems, DimitriAff5; Herbers, AlexandraAff6; Klein, Saskia K.Aff1, Aff7; de Jonge, SuzanAff8; Westerweel, Peter E.Aff9; Cruijsen, MarjanAff10; Hoogendoorn, MelsAff11; Cuijpers, MarlousAff12; Deeren, DriesAff13; Bailly, BenjaminAff14; Visser, OttoAff15; van Rhenen, AnnaAff16; Posthuma, Eduard F. M.Aff17; Valk, Peter J. M.Aff18; Cloos, JacquelineAff19; Ammatuna, EmanueleAff1; Refos, Jeannine M.Aff2; Fakkert, R.Aff2; Löwenberg, BobAff18; Ossenkoppele, Gert J.Aff19 |
| Source: |
Annals of Hematology. 104(1):361-368 |
| Database: |
Springer Nature Journals |